Central nervous system-directed preventative therapy in adults with lymphoma

British Journal of Haematology

Volumn 131, Issue 1, 2005, Pages 13-21

  McMillan, Andrew ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Central nervous system directed therapy; Intrathecal chemotherapy; Lymphoma; Lymphomatous meningitis

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IDARUBICIN; IDARUBICINOL; IFOSFAMIDE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; TUMOR MARKER;

ANATOMY; B CELL LYMPHOMA; BREAST TUMOR; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER PREVENTION; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PENETRATION; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TREATMENT FAILURE; EPIDURAL SPACE; EVIDENCE BASED MEDICINE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LYMPHOBLASTOMA; MEDIASTINUM TUMOR; MULTIVARIATE ANALYSIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NOSE TUMOR; PARANASAL SINUS TUMOR; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SPINAL CORD TUMOR; TARGET ORGAN; TESTIS TUMOR; TREATMENT OUTCOME; AGED; BLOOD; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; INTRASPINAL DRUG ADMINISTRATION; LYMPHOMA; MALE; MIDDLE AGED; RECURRENT DISEASE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; INJECTIONS, SPINAL; L-LACTATE DEHYDROGENASE; LYMPHOMA; LYMPHOMA, LYMPHOBLASTIC; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 27744553846     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05703.x     Document Type: Review

References (47)

1. van-Besien K. Ha C.S. Murphy S. McLaughlin P. Rodriguez A. Amin K. Forman A. Romaguera J. Hagemeister F. Younes A. Bachier C. Sarris A. Sobocinski K.S. Cox J.D. Cabanillas F. ( 1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood, 91, 1178 1184.
2. Balis F.M. Savitch J.L. Bleyer W.A. Reaman G.H. Poplack D.G. ( 1985) Remission induction of meningeal leukemia with high-dose intravenous methotrexate. Journal of Clinical Oncology, 3, 485 489.
3. Bashir R.M. Bierman P.J. Vose J.M. Weisenburger D.D. Armitage J.O. ( 1991) Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. American Journal of Clinical Oncology, 14, 478 482.
4. Batchelor T. Leahy N. Kaufman D. ( 2001) High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. Clinical Lymphoma, 2, 116 119.
5. Bishop P.C. Wilson W.H. Pearson D. Janik J. Jaffe E.S. Elwood P.C. ( 1999) CNS involvement in primary mediastinal large B-cell lymphoma. Journal of Clinical Oncology, 17, 2479 2485.
6. Bos G.M. van Putten W.L. van der Holt B. van den Bent M. Verdonck L.F. Hagenbeek A. ( 1998) For which patients with aggressive non-Hodgkin's lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Annals of Oncology, 9, 191 194.
7. Buckstein R. Lim W. Franssen E. Imrie K.L. ( 2003) CNS prophylaxis and treatment in non-Hodgkin's lymphoma: variation in practice and lessons from the literature. Leukaemia and Lymphoma, 44, 955 962.
8. Bunn Jr., P.A. Schein P.S. Banks P.M. DeVita Jr., V.T. ( 1976) Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood, 47, 3 10.
9. Cetto G.L. Iannucci A. Tummarello D. Rizzuto N. Sabbioni R. Menestrina F. ( 1981) Involvement of the central nervous system in non-Hodgkin's lymphoma. Tumori, 67, 39 44.
10. Chahal S. Lagera J.E. Ryder J. Kleinschmidt-DeMasters B.K. ( 2003) Hematological neoplasms with first presentation as spinal cord compression syndromes: a 10-year retrospective series and review of the literature. Clinical Neuropathology, 22, 282 290.
11. Chua S.L. Seymour J.F. Streater J. Wolf M.M. Januszewicz E.H. Prince H.M. ( 2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leukaemia and Lymphoma, 43, 1783 1788.
12. Coiffier B. Lepage E. Briere J. Herbrecht R. Tilly H. Bouabdallah R. Morel P. Van Den Neste E. Salles G. Gaulard P. Reyes F. Lederlin P. Gisselbrecht C. ( 2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235 242.
13. Cortes J. O'Brien S.M. Pierce S. Keating M.J. Freireich E.J. Kantarjian H.M. ( 1995) The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood, 86, 2091 2097.
14. Feugier P. Virion J.M. Tilly H. Haioun C. Marit G. Macro M. Bordessoule D. Recher C. Blanc M. Molina T. Lederlin P. Coiffier B. ( 2004) Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Annals of Oncology, 15, 129 133.
15. Fonseca R. Habermann T.M. Colgan J.P. O'Neill B.P. White W.L. Witzig T.E. Egan K.S. Martenson J.A. Burgart L.J. Inwards D.J. ( 2000) Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer, 88, 154 161.
16. Gholam D. Bibeau F. El Weshi A. Bosq J. Ribrag V. ( 2003) Primary breast lymphoma. Leukaemia and Lymphoma, 44, 1173 1178.
17. Haioun C. Besson C. Lepage E. Thieblemont C. Simon D. Rose C. Tilly H. Sonet A. Lederlin P. Attal M. Briere J. Reyes F. ( 2000a) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Annals of Oncology, 11, 685 690.
18. Haioun C. Lepage E. Gisselbrecht C. Salles G. Coiffier B. Brice P. Bosly A. Morel P. Nouvel C. Tilly H. Lederlin P. Sebban C. Briere J. Gaulard P. Reyes F. ( 2000b) Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. Journal of Clinical Oncology, 18, 3025 3030.
19. Harris N.L. Jaffe E.S. Stein H. Banks P.M. Chan J.K. Cleary M.L. Delsol G. De Wolf-Peeters C. Falini B. Gatter K.C. Grogan T.M. Isaacson P.G. Knowles D.M. Mason D.Y. Mullerhermelink H.K. Pileri S.A. Piris M.A. Ralfkiaer E. Warnke R.A. ( 1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 84, 1361 1392.
20. Hegde U. Filie A. Little R.F. Janik J.E. Grant N. Steinberg S.M. Dunleavy K. Jaffe E.S. Abati A. Stetler-Stevenson M. Wilson W.H. ( 2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood, 105, 496 502.
21. Hoelzer D. Gokbuget N. ( 2000) New approaches to acute lymphoblastic leukemia in adults: where do we go Seminars in Oncology, 27, 540 559.
22. Hollender A. Kvaloy S. Lote K. Nome O. Holte H. ( 2000) Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis. European Journal of Cancer, 36, 1762 1768.
23. Jaffe E.S. Harris N.L. Stein H. Vardiman JW ( 2001) WHO Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissue. IARC Press, Lyon.
24. Jolivet J. ( 1987) Biochemical and pharmacologic rationale for high-dose methotrexate. NCI Monographs, 5, 61 65.
25. Keldsen N. Michalski W. Bentzen S.M. Hansen K.B. Thorling K. ( 1996) Risk factors for central nervous system involvement in non-Hodgkins-lymphoma - a multivariate analysis. Acta Oncologica, 35, 703 708.
26. Levitt L.J. Dawson D.M. Rosenthal D.S. Moloney W.C. ( 1980) CNS involvement in the non-Hodgkin's lymphomas. Cancer, 45, 545 552.
27. Liang R. Chiu E. Loke S.L. ( 1990) Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematological Oncology, 8, 141 145.
28. Litam J.P. Cabanillas F. Smith T.L. Bodey G.P. Freireich E.J. ( 1979) Central nervous system relapse in malignant lymphomas: risk factors and implications for prophylaxis. Blood, 54, 1249 1257.
29. MacKintosh F.R. Colby T.V. Podolsky W.J. Burke J.S. Hoppe R.T. Rosenfelt F.P. Rosenberg S.A. Kaplan H.S. ( 1982) Central nervous system involvement in non-Hodgkin's lymphoma: an analysis of 105 cases. Cancer, 49, 586 595.
30. Magrath I. Adde M. Shad A. Venzon D. Seibel N. Gootenberg J. Neely J. Arndt C. Nieder M. Jaffe E. Wittes R.A. Horak I.D. ( 1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. Journal of Clinical Oncology, 14, 925 934.
31. Mead G.M. Sydes M.R. Walewski J. Grigg A. Hatton C.S. Pescosta N. Guarnaccia C. Lewis M.S. McKendrick J. Stenning S.P. Wright D. ( 2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology, 13, 1264 1274.
32. Milpied N. Deconinck E. Gaillard F. Delwail V. Foussard C. Berthou C. Gressin R. Lucas V. Colombat P. Harousseau J.L. ( 2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. New England Journal of Medicine, 350, 1287 1295.
33. Moreton P. Morgan G.J. Gilson D. Smith G.M. McVerry B.A. Davies J.M. Mackie M.J. Bolam S. Jalihal S.S. Howard M.R. Parapia L.A. Williams A.T. Child J.A. ( 2004) The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen. Cancer Chemotherapy and Pharmacology, 53, 324 328.
34. Pennacchio L. Orlandini M. ( 1969) Immunoglobulin diseases. (Basis of modern immunology. Clinical contribution. Bing-Neel syndrome). Policlinico Sezione Practica, 76, 401 422.
35. Pfreundschuh M. Trumper L. Kloess M. Schmitz N. Schmits R. Glass B. Hasenclever D. Engert A. Rudolph C. Illiger J. Hossfeld D. Rube C. Loeffler M. for the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) ( 2004a) 2-Weekly CHOP (CHOP14): the new standard regimen for patients with aggressive non-Hodgkins lymphoma (NHL) >60 years of age. Blood, 104, 634 641.
36. Pfreundschuh M. Trumper L. Kloess M. Schmits R. Feller A.C. Rudolph C. Reiser M. Hossfeld D.K. Metzner B. Hasenclever D. Schmitz N. Glass B. Rube C. Loeffler M. ( 2004b) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104, 626 633.
37. Pinkel D. Woo S. ( 1994) Prevention and treatment of meningeal leukemia in children. Blood, 84, 355 366.
38. Rubenstein J.L. Combs D. Rosenberg J. Levy A. McDermott M. Damon L. Ignoffo R. Aldape K. Shen A. Lee D. Grillo-Lopez A. Shuman M.A. ( 2003) Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood, 101, 466 468.
39. Shikama N. Oguchi M. Sasaki S. Shinoda A. Nishikawa A. Arakawa K. Koiwai K. Mochizuki K. Yamada A. Watanabe T. Kadoya M. ( 2001) Evaluation of central nervous system involvement in nasal lymphomas. Nippon Igaku Hoshasen Gakkai Zasshi, 61, 342 346.
40. Spevak J. ( 1964) The prophylaxis of meningeal leukemia with intrathecal methotrexate. Journal of Iowa Medical Society, 54, 238 244.
41. The Non-Hodgkin's Lymphoma Pathologic Classification Project ( 1982) National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer, 49, 2112 2135.
42. Tilly H. Lepage E. Coiffier B. Blanc M. Herbrecht R. Bosly A. Attal M. Fillet G. Guettier C. Molina T.J. Gisselbrecht C. Reyes F. ( 2003) Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284 4289.
43. Wolf M.M. Olver I.N. Ding J.C. Cooper I.A. Liew K.H. Madigan J.P. ( 1985) Non-Hodgkin's lymphoma involving the central nervous system. Australasian and New Zealand Journal of Medicine, 15, 16 21.
44. Yamazaki H. Hanada M. Kitada M. Kuyama J. Sato T. Nishikubo M. Ishida T. Inoue T. Inoue T. ( 2003) Four cases of central nervous system involvement of breast malignant lymphoma. Japanese Journal of Clinical Oncology, 33, 399 403.
45. Zinzani P.L. Magagnoli M. Frezza G. Prologo G. Gherlinzoni F. Bendandi M. Albertini P. Babini L. D'Alessandro R. Tura S. ( 1999) Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leukaemia and Lymphoma, 32, 571 576.
46. Zucca E. Roggero E. Bertoni F. Conconi A. Cavalli F. ( 1999) Primary extranodal non-Hodgkin's lymphomas. Part 2: head and neck, central nervous system and other less common sites. Annals of Oncology, 10, 1023 1033.
47. Zucca E. Conconi A. Mughal T.I. Sarris A.H. Seymour J.F. Vitolo U. Klasa R. Ozsahin M. Mead G.M. Gianni M.A. Cortelazzo S. Ferreri A.J. Ambrosetti A. Martelli M. Thieblemont C. Moreno H.G. Pinotti G. Martinelli G. Mozzana R. Grisanti S. Provencio M. Balzarotti M. Laveder F. Oltean G. Callea V. Roy P. Cavalli F. Gospodarowicz M.K. ( 2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. Journal of Clinical Oncology, 21, 20 27.